Bragar Eagel & Squire, P.C. Urges Investors of aTyr, Marex, Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines - aTyr Pharma (NASDAQ:ATYR)

aTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atyr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod

Marex Group (Nasdaq: MRX) said clients can post USDC as initial-margin collateral for CFTC-regulated cleared derivatives, under a July 16 program. The first end-to-end transaction used Prime Trading LLC posting USDC to Marex, with Coinbase providing custody and 1:1 conversion to dollars, and Marex handling valuation, haircuts, and reporting. CFTC staff letters 25-40 and 26-05 set conditions.

Keefe Bruyette raised its price target on Marex Group (NASDAQ:MRX) to $80 from $60 and kept an Outperform rating on July 9. The firm cited Marex’s plan to acquire Bright Point International, an Asia-focused clearing business, to expand in APAC and China. The deal adds about $800m in client balances and 70+ employees, subject to regulatory approval, expected late 2026 to early 2027.

Marex Group (MRX) said it will acquire Singapore-based Bright Point International to expand its Asia-Pacific footprint and access China markets. Terms were not disclosed. Marex expects added revenue from new clients and higher balances, plus synergies from internalizing some clearing activities. The deal would add about $800m in client balances and 70+ employees, with closing targeted for late 2026 or early 2027.

Marex Group Limited (NASDAQ: MRX) agreed to acquire Bright Point International (BPI), a Singapore-based multi-asset clearing business focused on Asia Pacific and China-linked clients. The deal adds about $800m in client balances and 70+ employees, and is expected to close late 2026 or early 2027, subject to regulatory approval.

MoonLake Immunotherapeutics (NASDAQ: MLTX) priced an underwritten public offering of 9,000,000 Class A ordinary shares at $20.00 each, plus pre-funded warrants for up to 1,000,000 shares at $19.9999. Gross proceeds are expected at about $200 million. An option allows underwriters to buy 1,500,000 more shares. Net proceeds will fund sonelokimab development and general corporate purposes; closing is expected around June 25, 2026.